Lianyungang, China

Xujing Tang

USPTO Granted Patents = 2 

Average Co-Inventor Count = 14.7

ph-index = 1


Company Filing History:


Years Active: 2025

where 'Filed Patents' based on already Granted Patents

2 patents (USPTO):

Title: The Innovative Contributions of Xujing Tang

Introduction

Xujing Tang is a prominent inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective BCL-2 inhibitors. With a total of two patents to his name, Tang's work focuses on innovative compounds that have the potential to treat cancer and other related diseases.

Latest Patents

Xujing Tang's latest patents include a trifluoromethyl-substituted sulfonamide as a BCL-2-selective inhibitor. This invention discloses a compound of formula I, along with its stereoisomers and pharmaceutically acceptable salts. The preparation method and pharmaceutical composition are also detailed, highlighting the compound's uses in treating anti-apoptotic BCL-2-related diseases, such as cancer. Another notable patent is for a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor. This patent similarly outlines a compound of formula I, its stereoisomers, and preparation methods, emphasizing its application in treating diseases related to the anti-apoptotic protein BCL-2.

Career Highlights

Xujing Tang is currently associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His work at this esteemed pharmaceutical company has allowed him to focus on groundbreaking research and development in the field of cancer treatment. His innovative approach and dedication to improving therapeutic options have positioned him as a key figure in pharmaceutical advancements.

Collaborations

Xujing Tang has collaborated with notable colleagues, including Fei Liu and Yanlong Liu. These partnerships have fostered a collaborative environment that enhances the research and development process, leading to significant advancements in their field.

Conclusion

Xujing Tang's contributions to the pharmaceutical industry, particularly in the development of BCL-2-selective inhibitors, showcase his innovative spirit and commitment to addressing critical health challenges. His work continues to pave the way for new treatment options in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…